



**Contact:** Marc R. Viscogliosi  
**Tel:** (212) 367-7274, Ext. 2103  
**Email:** [marc.viscogliosi@paradigmspine.com](mailto:marc.viscogliosi@paradigmspine.com)

**FOR IMMEDIATE RELEASE**

**PARADIGM SPINE, LLC ANNOUNCES HIGHMARK, INC. IS 1<sup>ST</sup> PRIVATE PAYOR TO ISSUE  
EXCLUSIVE POSITIVE COVERAGE POLICY FOR COFLEX<sup>®</sup> INTERLAMINAR STABILIZATION<sup>®</sup>  
TREATMENT OF LUMBAR SPINAL STENOSIS**

- **Lumbar Spinal Stenosis Affects 1.6 million U.S. Patients Annually**
- **Medical coverage policy issued by Highmark, Inc. and affiliates operating health insurance plans for 5.0 million members in Pennsylvania (PA), West Virginia (WV), and Delaware (DE)**
- **Exclusive coverage policy specifically for *coflex<sup>®</sup>* Interlaminar Stabilization<sup>®</sup>**
- ***coflex<sup>®</sup>* is a non-fusion, motion-preserving implant for treatment of Lumbar Spinal Stenosis**
- **Highmark, Inc. and its health insurance subsidiaries and affiliates collectively are among the 10 largest health insurers in the U.S. and comprise the 4<sup>th</sup> largest Blue Cross and Blue Shield-affiliated organization**
- **This Highmark policy is in addition to the already 5.5 million lives covered by Medicare, Medicaid & Affordable Care Act marketplace throughout the states of PA, WV and DE**
- **Total coverage for *coflex<sup>®</sup>* now at 10.5 million lives throughout PA, WV and DE**

**New York, NY November 20, 2017** – Paradigm Spine, LLC, a leader in providing solutions for the treatment of lumbar spinal stenosis announces issuance of a Highmark, Inc. Medical Policy, entitled “Interspinous and Interlaminar Stabilization/Distractor Devices (Spacers)” dated November 6, 2017. The coverage policy may be found here <https://www.highmarkbcbswv.com/west-virginia-commercial-medical-policy/S-191-016.html>

Importantly, the Medical Policy specifically excludes any other interspinous distraction or interlaminar stabilization devices, other than the *coflex<sup>®</sup>* device, from coverage. Highmark, Inc. is the first commercial insurance carrier to provide exclusive coverage for the *coflex<sup>®</sup>* device, due to the more than 85 peer-reviewed published articles supporting the safety and effectiveness of the *coflex<sup>®</sup>* technology.

Lumbar spinal stenosis (“LSS”), affecting 1.6 million patients annually, is a debilitating and degenerative disease in older patients (>50 yrs) often associated with significant leg and back pain, leg numbness and weakness, causing a significant reduction in an active lifestyle. Traditional surgical treatment options for LSS includes a decompression that removes bone and soft tissue and may also require a fusion to stabilize the spine. The *coflex<sup>®</sup>* device is a non-fusion, motion preserving stabilization implant, that is FDA PMA approved for the treatment of Lumbar Spinal Stenosis, and can be used in conjunction with a decompression or used in lieu of a spinal fusion.

To learn more about *coflex<sup>®</sup>* Interlaminar Stabilization<sup>®</sup>, please visit [www.coflexsolution.com](http://www.coflexsolution.com).

Marc Viscogliosi, Chairman & CEO – “With over 85 peer-review published articles, including landmark 5 year follow-up studies, medical society guidelines, and now with commercial insurance coverage, it is wonderful to be able to expand patient access to the *coflex<sup>®</sup>* technology. We are particularly gratified by the recognition of Highmark to exclusively cover *coflex<sup>®</sup>* as the only interlaminar/interspinous device treatment option for LSS.”

#### **About Paradigm Spine, LLC**

Paradigm Spine, LLC was founded in 2004 and remains focused on the design and development of solutions for the disease management of spinal stenosis. The Company's signature product is the *coflex<sup>®</sup>* Interlaminar Stabilization<sup>®</sup> device, which has more than 20 years of clinical history and patients treated in more than 40 countries worldwide.